# An Phase III Study of Recombinant Anti-IL-17A Humanized Monoclonal Antibody in Chinese Participants With PsO

> **NCT06299982** · PHASE3 · UNKNOWN · sponsor: **Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.** · enrollment: 750 (estimated)

## Conditions studied

- Plaque Psoriasis Patients

## Interventions

- **DRUG:** 608 Q2W
- **DRUG:** 608 Q4W

## Key facts

- **NCT ID:** NCT06299982
- **Lead sponsor:** Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2024-05-15
- **Primary completion:** 2025-01-30
- **Final completion:** 2025-03-20
- **Target enrollment:** 750 (ESTIMATED)
- **Last updated:** 2024-03-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06299982

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06299982, "An Phase III Study of Recombinant Anti-IL-17A Humanized Monoclonal Antibody in Chinese Participants With PsO". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06299982. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*